Clarify the Scope and Strategy for Non-Dilutive Funding
Establish the exact strategic objectives for securing biomedical grant funding and non-dilutive capital for the venture. Define how non-dilutive funds will de-risk core scientific and clinical milestones without compromising equity or operational autonomy. Map out the specific grant bodies, such as Innovate UK or the NIHR, that align with the venture's technology readiness level.
Defining the precise scope prevents wasted effort on misaligned grant calls and misdirected proposals. This foundational clarity ensures the non-dilutive funding strategy directly reinforces the overarching venture valuation and investor readiness timeline.
Produce a strategic brief detailing the non-dilutive target landscape, target grant funds, and explicit operational objectives for the capital. The output must clearly articulate how securing these funds protects founder equity while advancing technology validation.
Five questions an expert would ask when reviewing your output
Use these to challenge assumptions, pressure-test your logic, and check the quality of this action's output in the context of the parent task and wider venture development.
- 1
What specific scientific or clinical milestone will this non-dilutive funding de-risk before you raise your next equity round?
- 2
How did you determine that non-dilutive grant funding is more appropriate for this development stage than dilutive venture capital?
- 3
Which specific funding bodies or grant programmes have you shortlisted, and why do their scope requirements match your current technology readiness level?
- 4
How does securing this non-dilutive capital preserve your equity cap table and improve your post-money valuation in subsequent investment rounds?
- 5
What operational risks or delays might arise if grant body approval takes longer than your current cash runway allows?